Journal article
Comparison of gastrointestinal side effects from different doses of azithromycin for the treatment of gonorrhoea
JJ Ong, I Aguirre, M Unemo, FYS Kong, CK Fairley, JS Hocking, EPF Chow, W Tieosapjaroen, J Ly, MY Chen
Journal of Antimicrobial Chemotherapy | Published : 2022
DOI: 10.1093/jac/dkac118
Abstract
Objectives: Azithromycin is commonly used to treat Neisseria gonorrhoeae. We compared its gastrointestinal side effects using 1g single, 2g single or 2g split (i.e. 1g plus 1g 6-12h later) dosing, representing our clinic's changing guidelines over the study period. Methods: We recruited consecutive sexual health clinic patients who received azithromycin (and 500mg ceftriaxone) for uncomplicated gonorrhoea. Each patient received a text message 48h after their attendance to complete a questionnaire. Results: Patients received 1g single (n=271), 2g single (218) or 2g split (105) doses. Vomiting was less common for 1g versus 2g single dose [1.1% versus 3.7%; risk difference (RD):-2.6%; 95% CI:-0..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by the Australian National Health and Medical Research Council (NHRMC). J.J.O. and E.P.F.C. are each supported by an Australian NHMRC Emerging Leadership Investigator Grant (GNT1193955 and GNT1172873, respectively). C.K.F. is supported by an Australian NHMRC Leadership Investigator Grant (GNT1172900). J.S.H. is supported by an Australian NHMRC Senior Research fellowship (GNT1136117).